Core Innovative Technology

One of the hallmarks of Alzheimer’s disease is the formation of amyloid plaques in the brain, comprised mainly of amyloid beta peptides. ReXceptor aims to restore and enhance the brain’s natural clearance mechanisms of amyloid-beta by administering a retinoid X receptor (RXR) agonist.

Reversal of Alzheimer’s disease in Mice

Preliminary data from the laboratory of ReXceptor’s co-founder, Dr. Gary Landreth, demonstrates that treatment of Alzheimer’s disease mice with bexarotene (an RXR agonist), results in the rapid reduction of soluble forms of amyloid that is associated with the reversal of memory and cognition over a few days.

Find Out More

Contact Us for full scientific and commercialization details.
Michael Haag, CEO
michael@rexceptor.com
(216) 544-7965

This site is under development. Email us now for an alert when our new site launches in the near future.